J. Eglītis

Delays in diagnosis and treatment of breast cancer: a multinational analysis

Jacek Jassem, Vahit Özmen, Florin Bacanu et al. · European Journal of Public Health · 2013 · 145 citations · Full text

Evaluation of the pharmacodynamics and pharmacokinetics of the PARP inhibitor olaparib: a Phase I multicentre trial in patients scheduled for elective breast cancer surgery

Nigel Bundred, Jānis Gardovskis, Janusz Jaśkiewicz et al. · Investigational New Drugs · 2013 · 88 citations

Parp Inhibitor Olaparib, Surgical Oncology, Breast Oncology +9

High prevalence of two BRCA1 mutations, 4154delA and 5382insC, in Latvia

L. P. Tikhomirova, Olga Siņicka, Dagnija Smite et al. · Familial Cancer · 2005 · 54 citations

Brca1 Mutations, Somatic Variant, Genetic Disorder +9

Extracellular Vesicles as Biomarkers and Therapeutic Targets in Breast Cancer.

Lilite Sadovska, J. Eglītis, Aija Linē · PubMed · 2015 · 54 citations

Breast Oncology, Immunology, Pathology +16

Prognostic relevance of carbonic anhydrase IX expression is distinct in various subtypes of breast cancer and its silencing suppresses self-renewal capacity of breast cancer cells

Lāsma Ivanova, Elīna Zandberga, Karīna Siliņa et al. · Cancer Chemotherapy and Pharmacology · 2014 · 52 citations

Breast Oncology, Oncology, Self-renewal Capacity +7